Desmopressin may not reduce hematoma expansion in ICH associated with antiplatelet therapy
Desmopressin administration in patients with spontaneous antiplatelet-associated ICH is not associated with a reduction in poor outcomes, according to a recent study published in the Journal of the Neurological Sciences
Researchers conducted a study to evaluate the impact of desmopressin acetate (DDAVP) on poor outcomes, hematoma expansion, and adverse events in patients diagnosed with a non-traumatic, antiplatelet-associated intracranial hemorrhage (ICH).
This was a multicenter, retrospective, propensity-matched cohort study comparing DDAVP to control in patients diagnosed with a non-traumatic ICH previously on antiplatelet therapy. Notable exclusion criteria included admission to trauma service, subarachnoid hemorrhages, confounding coagulopathic factors, and hematoma evacuation. Poor outcome, defined as discharge to hospice or in-patient mortality, was the primary outcome. Secondary outcomes included intracranial hematoma expansion and occurrence of adverse events, which included hyponatremia and thromboembolic events.
Results:
A total of 49 patients receiving DDAVP were compared to 107 controls in the unmatched cohort. Thirty-seven patients treated with DDAVP and 55 controls were included in the propensity-matched analysis, which was adjusted for age, ethnicity, history of diabetes, receipt of platelet transfusion, and thromboembolism prophylaxis. Poor outcome (16.2% DDAVP vs 29% control, p = 0.13), rates of hematoma expansion (11.8% DDAVP vs 11.1% control, p = 0.99), and adverse events (21.6% DDAVP vs 20% control, p = 0.99) were statistically similar between the matched groups.
Thus, DDAVP administration in patients with spontaneous antiplatelet-associated ICH was not associated with a reduction in poor outcomes, hematoma expansion, or an increase in adverse events. Use of DDAVP in this patient population appears to be safe. Larger prospective studies are warranted to evaluate DDAVP utility in this patient population.
Reference:
Effect of desmopressin acetate on acute spontaneous intracranial hemorrhage in patients on antiplatelet therapy J. Neurol. Sci. 2022 Jan 06;434(2022)120142, J McManus, J Ferreira, GM Jones, KS Smetana, M Smith Condeni, K Berger, C Witenko, C Smotherman, S Gautam, MA Pizzi, MJ Erdman.
https://pubmed.ncbi.nlm.nih.gov/35081458/
